Erste Zwischenergebnisse aus BioNTechs und BMS‘ globaler Phase-2-Studie mit bispezifischem PD-L1xVEGF-A-Antikörperkandidat Pumitamig (BNT327/BMS986545) zeigen ermutigende Anti-Tumor-Aktivität bei fortgeschrittenem kleinzelligem Lungenkrebs
SOPHiA GENETICS en Jessa Ziekenhuis kondigen samenwerking aan op het gebied van precisieoncologie tijdens het European Congress of Pathology USA - Nederlands USA - English USA - English USA - Français USA - Deutsch
Streamex Exchange Corp NASDAQ-BSGM Creates a Tokenized Yield-Bearing Gold Product Generating up-to 4% through Exclusive Partnership with Monetary Metals
New Fluke GFL-1500 Quickly Locates Ground Faults to Boost Solar System Uptime
Zai Lab to Present Data from Phase 1 Trial of DLL3-Targeted Antibody-Drug Conjugate (ADC) ZL-1310 at 2025 ASCO Annual Meeting
Zai Lab to Present New Data from Internally Developed, Next-Generation Oncology Candidates at AACR 2025 Annual Meeting
New Form 8-K - ETHZilla Corp Filed: 2025-09-08 AccNo: 0001213900-25-085321 Size: 627 KB Item 1.01: Entry into a Material Definitive Agreement Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item …